WOBURN, Mass. Jan. 26, 2011
The Angio Qx Immunoassay is a member of the Avantra QPDx™ biomarker detection product line for use with the Q400 Biomarker Workstation. This platform consists of a completely self-contained immunoassay BioChip and instrument, for use in the automated measurement of key biomarkers.
Avantra is currently working with leading experts and institutions on the development of additional biomarker panels directed at specific diseases with an emphasis in the field of oncology for research use only (RUO). Avantra intends to seek regulatory approval for its assay technologies in the future.
The power and simplicity of Avantra's QPDx platform offers users a rapid, easy-to-use, high quality bench top quantitative multiplex protein assay platform with extremely low CVs and very little setup time.
About Avantra Biosciences Corporation
Avantra Biosciences is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.
Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.
SOURCE Avantra Biosciences